Remotely Monitored Exercise Interventions in Patients With mCSPC Undergoing ADT (Prostate 006)

Eligibility Criteria

• 1. Provision of signed and dated informed consent form
• 2. Stated willingness to comply with all study procedures and availability for the duration of the study
• 3. Male, aged ≥18 years old
• 4. Diagnosis of mCSPC (defined as either biopsy-proven metastatic prostate cancer or elevated PSA (Prostate Specific Antigen) in the setting of imaging findings typical of prostate cancer spread; patients can either have de novo metastatic disease or recurrent metastatic disease after prior definitive therapy to the primary tumor with either surgery or radiation)
• 5. Planned treatment with ADT (LHRH \[Luteinizing hormone-releasing hormone\] agonist such as leuprolide or LHRH antagonist such as degarelix), and intensification with ARSI (abiraterone/prednisone, enzalutamide, apalutamide, or darolutamide)
• 6. Oncologist clearance for exercise training after taking into account functional status and co-morbid conditions that may limit ability to participate.
• 7. Ability to take oral medication and willing to adhere to the study intervention regimen
• 8. Ability to read, speak, and understand English.
• 1. Castrate-resistant prostate cancer (defined as prostate cancer previously treated with a backbone of ADT hormonal therapy with either progression of disease on imaging PSA progression with PSA increase of \> 25% and 2 ng/mL above nadir, confirmed at 2 time points at least 3 weeks apart, in the setting of testosterone level \< 50)
• 2. Patients with prostate cancer with biochemical recurrence (e.g., received prior definitive therapy with subsequent PSA \[Prostate-Specific Antigen\] rise) but radiographic imaging is negative for metastatic disease
• 3. Metastatic bone lesion(s) in the proximal femur, bone lesion causing impending fracture, or other metastatic site deemed unsafe for walking by treating physician
• 4. Medical/orthopedic comorbidities that preclude stationary cycling or walking
• 5. Significant cardiac/renal/hepatic/hematological/pulmonary disease precluding exercise training
• 6. Unstable angina or myocardial infarction within 4-weeks prior to treatment
• 7. Complex ventricular arrhythmias or New York Heart Association class IV symptoms
• 8. Symptomatic severe aortic stenosis
• 9. Acute pulmonary embolus
• 10. Acute myocarditis
• 11. Untreated high-risk proliferative retinopathy
• 12. Recent retinal hemorrhage
• 13. Uncontrolled hypertension (systolic blood pressure \> 180 mm Hg or diastolic blood pressure \> 120 mm Hg)
• 14. Severe baseline electrolyte abnormalities (e.g. potassium) that may predispose patient to arrhythmias in the opinion of the treating investigator
• 15. Uncontrolled metabolic disease (diabetes with fasting blood sugar \>300 mg/dl, thyrotoxicosis, myxedema)
• 16. Symptomatic peripheral vascular disease
• 17. Prior treatment with taxane- or platinum- based chemotherapy
• 18. Prior treatment with PARP \[Poly (ADP-ribose) polymerase\] inhibitors
• 19. Prior treatment with radium-223 or lutetium-177